Zevra Therapeutics
Zevra Therapeutics
ZVRA
NASDAQ
7.65
USD
-10.42%
About
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets.
Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy.
Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 557.2K |
| Three Month Average Volume | 15.6M |
| High Low | |
| Fifty-Two Week High | 8.4399 USD |
| Fifty-Two Week Low | 3.89 USD |
| Fifty-Two Week High Date | 05 Aug 2024 |
| Fifty-Two Week Low Date | 13 Nov 2023 |
| Price and Volume | |
| Current Price | 7.65 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | 14.94% |
| Thirteen Week Relative Price Change | 53.71% |
| Twenty-Six Week Relative Price Change | -1.73% |
| Fifty-Two Week Relative Price Change | 20.41% |
| Year-to-Date Relative Price Change | -1.37% |
| Price Change | |
| One Day Price Change | 3.52% |
| Thirteen Week Price Change | 64.52% |
| Twenty-Six Week Price Change | 8.05% |
| Five Day Price Change | 6.55% |
| Fifty-Two Week Price Change | 50.89% |
| Year-to-Date Price Change | 16.79% |
| Month-to-Date Price Change | 17.87% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.48945 USD |
| Book Value Per Share (Most Recent Quarter) | 0.77344 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | -0.29046 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | -0.91392 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.78982 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.77459 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.61064 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.29889 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.66925 USD |
| Normalized (Last Fiscal Year) | -1.29889 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.29889 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.66925 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.29889 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.66925 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.63085 USD |
| Cash Per Share (Most Recent Quarter) | 1.17305 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.26942 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.57161 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.4334 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -74 |
| Cash Flow Revenue (Trailing Twelve Months) | -235 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -273.36% |
| Pretax Margin (Last Fiscal Year) | -167.69% |
| Pretax Margin (5 Year) | -128.48% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 97.09% |
| Gross Margin (Trailing Twelve Months) | 71.78% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -180.63% |
| Operating Margin (Trailing Twelve Months) | -309.83% |
| Operating Margin (5 Year) | -136.89% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -167.69% |
| Net Profit Margin (Trailing Twelve Months) | -274.10% |
| Net Profit Margin (5 Year) | -128.42% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -47.47% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | 45.00% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | 27.38% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 69.75% |
| Total Debt (5 Year) | -12.22% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | -526.55% |
| EPS Change (Trailing Twelve Months) | -244.50% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | -100,000 |
| Price to Tangible Book (Most Recent Quarter) | -100,000 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | 9.1M |
| Net Debt (Last Fiscal Year) | -24,971,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 15 |
| Price to Sales (Trailing Twelve Months) | 17 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 5 |
| Price to Book (Most Recent Quarter) | 10 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 8 |
| Long Term Debt to Equity (Most Recent Quarter) | 180 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 1 |
| Current Ratio (Most Recent Quarter) | 2 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -33,831,000 |
| Free Cash Flow (Trailing Twelve Months) | -56,304,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 69 |
| Total Debt to Equity (Most Recent Quarter) | 180 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -32.02% |
| Return on Assets (Trailing Twelve Months) | -52.61% |
| Return on Assets (5 Year) | -32.11% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -67.23% |
| Return on Equity (Trailing Twelve Months) | -130.22% |
| Return on Equity (5 Year) | -293.13% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -45.61% |
| Return on Investment (Trailing Twelve Months) | -65.34% |
| Return on Investment (5 Year) | -39.89% |